MEK inhibitor

Selumetinib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

melanoma  

encorafenib plus binimetinib  
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting-46%
selumetinib  
Kirkwood, 2012     selumetinibtemozolomide -
Kirkwood   selumetinibtemozolomide -
trametinib + dabrafenib  
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting-61%
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting-25%-37%
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting-44%-31%
vemurafenib and cobimetinib  
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting-49%